InvestorsHub Logo
icon url

d0lphint0m

02/01/20 4:09 PM

#54621 RE: thedonald123 #54613

Where is your stop loss?

I knew a guy who lost it all in 1973 being short the wrong thing when the news came out against him. He lost millions, then his wife, then his life. It was very sad to see as a new broker.
icon url

bwolfy2002

02/01/20 11:59 PM

#54659 RE: thedonald123 #54613

I don’t believe this for a heart beat. But best of luck to you with that....
icon url

plavac

02/02/20 3:40 AM

#54662 RE: thedonald123 #54613

You are short this.

"The receptor CCR5, targeted by HIV drugs, is also key in driving prostate cancer metastases, suggesting that blocking this molecule could slow prostate cancer spread."
https://www.sciencedaily.com/releases/2014/12/141201090311.htm

" The downregulation of CCR5 appears to suppress cervical cancer cell invasion."
https://www.spandidos-publications.com/10.3892/etm.2015.2911

"Thus, blocking CCR5/CCL5 axis might prove beneficial to prevent metastasis and provide a more therapeutic strategy to control Pancreatic cancer progression."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778036/

"The activation of the receptor CCR5 in breast cancer cells controls their invasiveness serving as a driver for metastasis. Furthermore, the CCL5/CCR5 axis participates in the recruitment of specific immune cells into tumors, inducing local immunosuppression and favoring tumor progression."
https://www.researchgate.net/publication/266247222_The_potential_to_target_CCL5CCR5_in_breast_cancer

"We found that CCR5 was more abundant in melanoma cells than normal cells and was positively associated with tumor malignancy in clinical patients."
https://onlinelibrary.wiley.com/doi/abs/10.1002/path.5207

"Glioblastoma (GBM) is the most prevalent malignant primary brain tumor in adults and exhibits a spectrum of aberrantly aggressive phenotype.Recent studies have shown that the chemokine CCL5 and its receptor CCR5 play important roles in tumor invasion and metastasis."
https://www.ncbi.nlm.nih.gov/m/pubmed/26390883/

And so 22 types of cancers where CCR5 is over expressed, Leronlimab successfully blocks CCR5 without SAE on over 840 patients with HIV-1, some have been on Leronlimab for 5 years.


icon url

thedonald123

02/02/20 8:21 AM

#54668 RE: thedonald123 #54613

I covered once at .92 and re-shorted more. Covered again on that fall from 1.54 to 1.25 the other day. Decent return. Just checked . Currently at 36,525 shares short. Not cleaning up but green now.